Cambrex Corporation Company Profile (NYSE:CBM)

About Cambrex Corporation (NYSE:CBM)

Cambrex Corporation logoCambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:CBM
  • CUSIP: 13201110
  • Web:
  • Market Cap: $1.77 billion
  • Outstanding Shares: 32,729,000
Average Prices:
  • 50 Day Moving Avg: $53.13
  • 200 Day Moving Avg: $55.08
  • 52 Week Range: $38.30 - $62.95
  • Trailing P/E Ratio: 19.69
  • Foreward P/E Ratio: 17.00
  • P/E Growth: 1.16
Sales & Book Value:
  • Annual Revenue: $515.45 million
  • Price / Sales: 3.43
  • Book Value: $14.38 per share
  • Price / Book: 3.76
  • EBIDTA: $167.23 million
  • Net Margins: 17.70%
  • Return on Equity: 24.25%
  • Return on Assets: 16.45%
  • Current Ratio: 4.15%
  • Quick Ratio: 2.37%
  • Average Volume: 288,712 shs.
  • Beta: 2.25
  • Short Ratio: 9.07

Frequently Asked Questions for Cambrex Corporation (NYSE:CBM)

What is Cambrex Corporation's stock symbol?

Cambrex Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex Corporation's earnings last quarter?

Cambrex Corporation (NYSE:CBM) posted its quarterly earnings data on Friday, August, 4th. The company reported $0.76 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.76. The business earned $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company's revenue was up 13.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 earnings per share. View Cambrex Corporation's Earnings History.

When will Cambrex Corporation make its next earnings announcement?

Cambrex Corporation is scheduled to release their next quarterly earnings announcement on Friday, November, 3rd 2017. View Earnings Estimates for Cambrex Corporation.

What guidance has Cambrex Corporation issued on next quarter's earnings?

Cambrex Corporation updated its FY17 earnings guidance on Friday, August, 4th. The company provided earnings per share guidance of $3.00-3.12 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.03. The company issued revenue guidance of $525-545 million (+7-11%), compared to the consensus revenue estimate of $536.87 million.

Where is Cambrex Corporation's stock going? Where will Cambrex Corporation's stock price be in 2017?

3 brokerages have issued twelve-month target prices for Cambrex Corporation's stock. Their forecasts range from $61.00 to $70.00. On average, they anticipate Cambrex Corporation's share price to reach $65.67 in the next twelve months. View Analyst Ratings for Cambrex Corporation.

Who are some of Cambrex Corporation's key competitors?

Who are Cambrex Corporation's key executives?

Cambrex Corporation's management team includes the folowing people:

  • Steven Mark Klosk, President, Chief Executive Officer, Director
  • Tom George Vadaketh, Chief Financial Officer, Executive Vice President
  • Shawn P. Cavanagh, Chief Operating Officer, Executive Vice President
  • Gregory P. Sargen, Executive Vice President, Corporate Development and Strategy
  • Samantha M. Hanley, Vice President, General Counsel,Corporate Secretary
  • James G. Farrell, Vice President and Corporate Controller
  • Shlomo Yanai, Non-Executive Chairman of the Board
  • Rosina B. Dixon M.D., Independent Director
  • Claes Glassell, Independent Director
  • Louis J. Grabowsky, Independent Director

Who owns Cambrex Corporation stock?

Cambrex Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.36%), Vanguard Group Inc. (9.44%), William Blair Investment Management LLC (5.30%), Bank of New York Mellon Corp (4.90%), Dimensional Fund Advisors LP (4.08%) and Congress Asset Management Co. MA (3.98%). Company insiders that own Cambrex Corporation stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Leon J Hendrix, Jr, Louis J Grabowsky, Peter G Tombros, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex Corporation.

Who sold Cambrex Corporation stock? Who is selling Cambrex Corporation stock?

Cambrex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, William Blair Investment Management LLC, Russell Investments Group Ltd., Wells Fargo & Company MN, Principal Financial Group Inc., American Century Companies Inc., Kennedy Capital Management Inc. and TIAA CREF Investment Management LLC. Company insiders that have sold Cambrex Corporation stock in the last year include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex Corporation.

Who bought Cambrex Corporation stock? Who is buying Cambrex Corporation stock?

Cambrex Corporation's stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., FMR LLC, Congress Asset Management Co. MA, OxFORD Asset Management LLP, Renaissance Technologies LLC, Neumeier Poma Investment Counsel LLC, American Capital Management Inc. and Ameriprise Financial Inc.. View Insider Buying and Selling for Cambrex Corporation.

How do I buy Cambrex Corporation stock?

Shares of Cambrex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex Corporation's stock price today?

One share of Cambrex Corporation stock can currently be purchased for approximately $54.05.

MarketBeat Community Rating for Cambrex Corporation (NYSE CBM)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Cambrex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cambrex Corporation (NYSE:CBM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $65.67 (21.49% upside)

Analysts' Ratings History for Cambrex Corporation (NYSE:CBM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/6/2017StephensSet Price TargetBuy$61.00N/AView Rating Details
2/6/2017Craig HallumSet Price TargetBuy$70.00N/AView Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 -> $66.00N/AView Rating Details
2/11/2016Singular ResearchLower Price TargetBuy$63.00 -> $60.00N/AView Rating Details
2/1/2016SidotiInitiated CoverageBuy$60.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Cambrex Corporation (NYSE:CBM)
Earnings by Quarter for Cambrex Corporation (NYSE:CBM)
Earnings History by Quarter for Cambrex Corporation (NYSE CBM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017$0.48N/AView Earnings Details
8/4/2017Q2 2017$0.76$0.76$136.82 million$134.55 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.51$0.68$99.05 million$105.01 millionViewListenView Earnings Details
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.53$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.60$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.29$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.32$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.05$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cambrex Corporation (NYSE:CBM)
2017 EPS Consensus Estimate: $2.91
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.48$0.51$0.50
Q2 20172$0.71$0.74$0.73
Q3 20172$0.48$0.52$0.50
Q4 20172$1.18$1.20$1.19
Q1 20181$0.63$0.63$0.63
Q2 20181$0.87$0.87$0.87
(Data provided by Zacks Investment Research)


Dividend History for Cambrex Corporation (NYSE:CBM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cambrex Corporation (NYSE:CBM)
Insider Ownership Percentage: 2.48%
Institutional Ownership Percentage: 98.28%
Insider Trades by Quarter for Cambrex Corporation (NYSE:CBM)
Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)
Insider Trades by Quarter for Cambrex Corporation (NYSE:CBM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017Steven M KloskCEOSell12,000$51.53$618,360.00View SEC Filing  
8/1/2017Steven M KloskCEOSell12,000$61.39$736,680.00View SEC Filing  
7/3/2017Steven M KloskCEOSell12,000$59.66$715,920.00View SEC Filing  
6/12/2017Samantha HanleyVPSell14,000$57.56$805,840.00View SEC Filing  
6/6/2017Leon J Hendrix JrDirectorSell20,656$55.95$1,155,703.20View SEC Filing  
6/1/2017Steven M KloskCEOSell12,000$54.19$650,280.00View SEC Filing  
5/1/2017Steven M KloskCEOSell12,000$58.20$698,400.00View SEC Filing  
4/3/2017Steven M KloskCEOSell12,000$54.58$654,960.00View SEC Filing  
3/1/2017Steven M KloskCEOSell12,000$56.70$680,400.00View SEC Filing  
2/27/2017Shawn CavanaghCOOSell19,620$55.95$1,097,739.00View SEC Filing  
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.00View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.00View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.60View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.00View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.00View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.00View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.74View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.00View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.00View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.00View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.52View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.46View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.00View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.32View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.80View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.00View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.00View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.00View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.00View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.00View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.00View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cambrex Corporation (NYSE:CBM)
Latest Headlines for Cambrex Corporation (NYSE:CBM)
DateHeadline logoCambrex Corporation (CBM) Given Consensus Recommendation of "Hold" by Analysts - September 20 at 2:30 AM logoIs Cambrex Corporation (CBM) a Suitable Value Stock? - Nasdaq - September 19 at 10:01 PM logoIs Cambrex Corporation (CBM) a Suitable Value Stock? - September 19 at 5:01 PM logoCambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference - September 18 at 11:19 AM logoCambrex Corporation (CBM) versus Marinus Pharmaceuticals (MRNS) Financial Survey - September 9 at 10:26 AM logoCambrex Corporation (CBM) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 9 at 3:26 AM logoCambrex Corporation (CBM) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow - September 7 at 5:04 PM logoInsider Selling: Cambrex Corporation (CBM) CEO Sells 12,000 Shares of Stock - September 5 at 7:46 PM logoCambrex Corporation (CBM) Rating Lowered to Hold at ValuEngine - September 3 at 7:44 PM logoCambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility - Nasdaq - August 31 at 9:52 PM logoCambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility - August 31 at 1:25 AM logoCambrex to Present at Upcoming Investor Conferences in ... - GlobeNewswire (press release) - August 30 at 3:19 PM logoCambrex to Present at Upcoming Investor Conferences in September - August 30 at 9:55 AM logoBidaskClub Downgrades Cambrex Corporation (CBM) to Sell - August 27 at 9:50 PM logoCambrex Corporation (CBM) Given Consensus Rating of "Buy" by Analysts - August 26 at 2:58 AM logoCleantech Building Materials: Unaudited Interim Results to 30 June 2017 - August 25 at 6:44 PM logoETFs with exposure to Cambrex Corp. : August 21, 2017 - August 23 at 5:12 PM logoCambrex Corporation (CBM) Stock Rating Lowered by BidaskClub - August 12 at 3:18 PM logoIHS Markit Score downgrades Cambrex Corp to 21 out of 100, ranking positively in only one out of three available IHS Markit categories. - August 11 at 4:09 AM logoSee what the IHS Markit Score report has to say about Cambrex Corp. - August 10 at 6:06 PM logoCambrex Corp. :CBM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 - August 10 at 6:06 PM logoCambrex (CBM) Shares Cross Below 200 DMA - Nasdaq - August 9 at 5:11 PM logoQ3 2017 EPS Estimates for Cambrex Corporation (CBM) Raised by Analyst - August 9 at 8:10 AM logoCambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity at Its Charles City, Iowa Facility - August 8 at 9:45 PM logoCambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : August 8, 2017 - August 8 at 9:45 PM logoCambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity at Its Charles City, Iowa Facility - GlobeNewswire (press release) - August 8 at 4:43 PM logoQ1 2018 Earnings Estimate for Cambrex Corporation Issued By First Analysis (NYSE:CBM) - August 8 at 10:51 AM logoCambrex Corporation (NYSE:CBM) Rating Increased to Buy at BidaskClub - August 6 at 12:54 PM logoCambrex Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release) - August 5 at 4:30 PM logoEdited Transcript of CBM earnings conference call or presentation 4-Aug-17 12:30pm GMT - August 4 at 10:18 PM logoCambrex Reports Second Quarter 2017 Financial Results - August 4 at 5:16 PM logoCambrex posts 2Q profit - August 4 at 5:16 PM logoCambrex Corporation (CBM) Issues Quarterly Earnings Results, Hits Expectations - August 4 at 3:38 PM logoCambrex Corporation (CBM) Releases FY17 Earnings Guidance - August 4 at 9:28 AM logoETFs with exposure to Cambrex Corp. : August 3, 2017 - August 3 at 11:31 PM logoCambrex Corporation (NYSE:CBM) CEO Sells $736,680.00 in Stock - August 2 at 4:28 PM logoComparing Cambrex Corporation (NYSE:CBM) and Teligent (TLGT) - August 1 at 2:08 PM logoCambrex Corporation (CBM) Receives Consensus Recommendation of "Buy" from Brokerages - August 1 at 8:01 AM logoCambrex to Announce Second Quarter 2017 Financial Results on August 4, 2017 - July 31 at 4:55 PM logoCambrex Corporation (CBM) Set to Announce Quarterly Earnings on Monday - July 24 at 8:08 AM logoCambrex Corporation (CBM) Given Consensus Recommendation of "Buy" by Analysts - July 7 at 11:16 AM logoCleantech Building Materials: Grant of share options - July 7 at 5:39 AM logoSteven M. Klosk Sells 12,000 Shares of Cambrex Corporation (CBM) Stock - July 5 at 7:06 PM logoETFs with exposure to Cambrex Corp. : July 4, 2017 - July 4 at 9:48 PM logoCambrex Corporation (NYSE:CBM) Downgraded by Zacks Investment Research - July 4 at 7:44 PM featured highlights: Hitachi, Koninklijke DSM, Embotelladora Andina, Cambrex and Ituran Location and Control - July 3 at 5:00 PM logoCleantech Building Materials: AGM Report - June 30 at 5:05 PM logoThe Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics - June 22 at 11:23 AM logoCambrex Corporation (CBM) VP Samantha Hanley Sells 14,000 Shares - June 12 at 7:15 PM logoEnzo Biochem (ENZ) Looks Good: Stock Jumps 13.3% in Session - June 12 at 5:12 PM



Cambrex Corporation (CBM) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff